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Abstract
Purpose Ovarian carcinoma in most instances is diag-
nosed in an advanced stage which cannot be cured by
surgical tumor debulking alone. Standard adjuvant che-
motherapy usually follows surgical procedures. Yet, few
reliable predictive tissue markers exist for the response of
ovarian carcinoma to chemotherapy. In this study, we
evaluated the predictive value of IL-17- and FOXP3-
positive tumor immune cell infiltration (TICI) for response
to chemotherapy in ovarian carcinoma.
Methods Formalin fixed and paraffin embedded biopsies
of mostly high-grade primary serous ovarian carcinomas
and their matched recurrences were immunostained with
IL-17 and FOXP3 on a tissue microarray. Chemoresistance
was defined as tumor recurrence within 6 months of the
completion of platinum-based chemotherapy. In 94 and 90
biopsies, conclusive data for IL-17 and FOXP3 were
available, respectively.
Results IL-17, but not FOXP3-positive TICI, displayed a
significantly higher density in biopsies of chemosensitive
tumors (p = 0.01). No significant difference in the
expression of IL-17 and FOXP3 TICI was observed in all
paired primary and recurrent biopsies without respect to
chemoresponse (p = 0.77 and p = 0.87, respectively).
However, significantly more IL-17-positive recurrences
were encountered in the group of patients with chemo-
sensitive tumors (p = 0.008).
Conclusions High IL-17-positive TICI is indicative for
response to chemotherapy in ovarian carcinoma. Higher
frequency of IL-17-positive TICI might persist in recurrent
tumor tissues of chemosensitive biopsies, suggesting
repetitive platinum-based chemotherapy as an appropriate
therapy for patients with IL-17-positive recurrences.
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Introduction
Ovarian carcinoma is the fifth most common female cancer
with an incidence range of 5-15/1000000 in Europe, but the
most letal of all female genital carcinomas (Jemal et al.
2010; Ferlay et al. 2010; Bray et al. 2005). Due to late and
unspecific symptoms onset, it is in most instances diag-
nosed in advanced stages, which cannot be treated by
surgery alone. Adjuvant platinum-based chemotherapy
usually follows surgical debulking. The vast majority of
patients recur with chemoresistant disease.
In order to optimize adjuvant therapy, earlier studies of
ovarian cancer analyzed different markers predicting
response to platinum-based chemotherapy, but few markers
have been identified as useful (He et al. 2008; Sato et al.
1999; Polcher et al. 2010). It is known that tumor biology
influences tumor microenvironment and that tumor
behavior is not only affected by the biologic behavior of
the neoplastic cells. Evidence points to important influence
of tumor-infiltrating immune cells on prognosis and tumor
growth (Liotta and Kohn 2001; Stagg 2008; Uppaluri et al.
2008; Oble et al. 2009; Nosho et al. 2010). Tumor-infil-
trating lymphocytes (TILs) are frequently considered to
reflect host immune response to infiltrative neoplasms
(Takagi et al. 1989). They have been shown to infiltrate a
variety of tumors from different origins (Galon et al. 2006;
Su et al. 2010). In ovarian cancer, it was shown that
FOXP3 positive regulatory T (Treg) cell infiltration is
associated with decreased survival (Wolf et al. 2005; Curiel
et al. 2004; Polcher et al. 2010). Furthermore, it was shown
that ovarian cancer-associated CD4-positive Treg cells can
be converted into proinflammatory interleukin 17-produc-
ing helper T cells (Leveque et al. 2009). In addition, it is
known that IL-17 can be produced by granulocytes (Li
et al. 2010; Lin et al. 2011) and other immune cells of the
innate immune system (Cua and Tato 2010). The role of
IL-17 tumor immune cell infiltration (TICI) in ovarian
carcinoma is still debated. Kryczek et al. (2009) showed
that high density of IL-17-positive TICI is associated with
improved survival. The predictive value of IL-17- and
FOXP3-positive TICI regarding chemotherapy in ovarian
cancer therefore merits specific analysis. As the prognostic
role of these two immune markers in ovarian carcinoma is
well studied, we investigated their predictive value for
chemosensitivity in a cohort of primary ovarian carcinomas
and their matched recurrences (Stadlmann et al. 2006,
2007a, b, 2008).
Materials and methods
Patients
Tissues from ovarian serous carcinomas and their recur-
rences were collected from the Tissue Biobank Basel of the
Institutes of Pathology of the University Hospital of Basel
and the Cantonal Hospitals of Baden, Liestal and St. Gal-
len, Switzerland.
Mostly high-grade ovarian carcinomas (5.7 % FIGO
stage II, 84.3 % FIGO stage III and 4.3 % FIGO stage IV)
were included in this study after typing according to pre-
vious publications (Singer et al. 2002, 2003). A tissue
microarray (TMA) was constructed which was also used in
previous studies (Stadlmann et al. 2006, 2007a, b, 2008).
All patients had recurrences after initial surgery and at least
three cycles of platinum-based adjuvant chemotherapy.
The collective was clinically divided into chemoresistant or
chemosensitive tumors. Resistance was defined as recur-
rence occurring within 6 months after completion of plat-
inum-based chemotherapy (Jazaeri et al. 2005). The TMA
allowed investigation of tissues from ovarian carcinomas
and matched recurrences from the same patients (Stadl-
mann et al. 2006, 2007a, b, 2008). The clinical data,
including surgical and systemic treatment characteristics,
were collected from medical records. All personal data
were made anonymous. The present study was performed
according to the guidelines of the institutional review
boards of the participating institutions in compliance with
specific regard to ethical standards and patient confidenti-
ality. The use of this clinically annotated TMA for research
was approved by the Regional Ethics Committee previ-
ously (Stadlmann et al. 2006, 2007a, b, 2008).
Tissue microarray construction
Tissue samples fixed in 4 % buffered formalin and
embedded in paraffin were used to construct a TMA
(Sauter et al. 2003). Briefly, hematoxylin–eosin stained
sections were made from each selected primary block
(donor blocks) to define representative tissue regions.
Tissue cylinders (0.6 mm in diameter) were then punched
from the region of the donor block with the use of a
custom-made precision instrument (Beecher Instruments,
Silver Spring, MD, USA). Tissue cylinders were transferred
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to a 25 mm 9 35 mm paraffin block to produce the TMA
block used for the study. The resulting TMA block was cut
into 3 lm sections, which was transferred to glass slides by
use of the Paraffin Sectioning Aid System (Instrumedics,
Hackensacks, NJ, USA). Sections from the TMA block
were used for the different analyses.
Immunohistochemistry (IHC) and analysis
Standard indirect immunoperoxidase procedures (ABC-
Elite, Vectra Laboratories) were used for immunohisto-
chemistry with the following antibodies: purified poly-
clonal goat anti-human IL-17 antibody (R&D Systems,
Minneapolis, MN, USA), dilution 1:50, polyclonal rabbit
IL-17 antibody (sc-7927, H-132, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), dilution 1:10 and monoclonal
mouse anti-human FOXP3 (clone 236A/E7, Abcam,
Cambridge, UK), dilution 1:20. To generate the data used
for comparison to chemosensitivity, the purified polyclonal
goat anti-human IL-17 antibody (R&D Systems, Minne-
apolis, MN, USA) was used.
Positively stained TICI in the stroma was counted in
each tissue spot, representing approximately one high-
power field (4009), intravascular cells were excluded from
analysis (Fig. 1b, d). Staining was evaluated for specificity
and analyzed by two experienced observers (RD and GS).
Cutoff was 1 positive cell/punch for both markers. In 94
and 90 biopsies, conclusive data for IL-17 and FOXP3
were available in primary and matched recurrent carcino-
mas, respectively.
Validation analysis of IL-17 staining
It is known that cells of the innate immune system can
produce IL-17 (Cua and Tato 2010; Li et al. 2010; Lin et al.
2011). Even though that most of the IL-17-positive TICI
resembled morphologically lymphocytes granulocytes
seemed to stain for IL-17, too. Therefore, we performed a
validation staining with two different IL-17 antibodies to
assess specificity. The correlation between the two anti-
bodies (AF-317-NA, R&D systems and sc-7927 (H-132),
Santa Cruz Biotechnology) was strong and highly signifi-
cant (rs = 0.78; p \ 0.0001).
The majority of all biopsies (n = 94) were found to be
completely negative for IL-17 (n = 55). In the positive
biopsies, the number of IL-17 protein expressing cells
ranged from 1 to 93.
Statistical analysis section
Cutoff scores used to classify ovarian carcinomas with low
or high IL-17 or FOXP3 infiltration were obtained by
regression tree analysis, evaluating sensitivity and false
positive rate for the discrimination of survivors and non-
survivors, on all tumor samples (Zlobec et al. 2007). Spe-
cific scores were set at 1 positive cell/punch for both
markers. Wilcoxon and Fisher’s exact tests were used to
determine the association of IL-17 and FOXP3 infiltration
and clinicopathological features for continuous and cate-
gorical variables, respectively. Univariate recurrence-free
and overall survival analyses were carried out by the Kap-
lan–Meier method and compared by means of log rank test.
The assumption of proportional hazards was verified for
both markers by analyzing the correlation of Schoenfeld
residuals and the ranks of individual failure times. Any
missing clinicopathological information was assumed to be
missing at random. Subsequently, IL-17 and FOXP3 cell
infiltration data were entered into multivariate Cox
regression analysis and hazard ratios (HR), and 95 %
confidence intervals (CI) were used to determine
Fig. 1 IL-17- and FOXP3-specific staining in high-grade ovarian
carcinoma. Tumor punches are representative of low (panels a and
c) and high (panels b and d) density of IL-17-positive (panels a and
b) and FOXP3-positive (panels c and d) TICI. Magnification: 910
J Cancer Res Clin Oncol (2013) 139:1295–1302 1297
123
prognostic effects on survival time. Spearman’s rank cor-
relation was used to analyze the correlation between the
two different IL-17 antibodies and between IL-17 and
FOXP3. Statistical analyses were performed using SPlus
software (Version 6.1, Insightful Corporation, Seattle, WA,
USA) and SAS (V9.1, the SAS Institute, Cary, NC).
Results
Patient characteristics
Patient’s median age was 58.5 (34–77) in the chemosensitive
and 63 (27–77) in the chemoresistant group, respectively.
Recurrence-free and overall survival in the chemoresistant
group were significantly shorter than in the chemosensitive
group (2.2 ± 0.3 vs. 18.2 ± 2.0 months, p \ 0.0001 and
27 ± 5.3 vs. 49.6 ± 4.0 months, p = 0.0003, respectively).
Most patients (94.3 %) had histopathologically high-grade
serous papillary carcinomas, and the two groups were com-
parable according to the FIGO classification (p = 0.47).
Furthermore, the analysis of clinicopathological data of the
overall cohort by density of IL-17- and FOXP3-positive TICI
is summarized in Table 1.
IL-17-positive immune cell infiltration in paired
primary and recurrent ovarian carcinoma
Only 2 out of 14 (14.3 %) chemoresistant primary carcino-
mas were classified as positive for IL-17? immune cell
infiltration. In the chemosensitive subset, 18 out of 33
(54.5 %) primary carcinomas were positive for IL-17 cell
infiltration (Table 2). Similarly, 2 out of 14 (14.3 %) recur-
rent chemoresistant carcinomas and 17 out of 33 (51.5 %)
recurrent chemosensitive carcinomas were positive for IL-17,
respectively. Ten IL-17-negative primary carcinomas sam-
ples were positive in their corresponding recurrences.
Remarkably, only 2 of them belonged to the chemoresistant
patients subset. Nine samples from the chemosensitive
patients subset retained their positivity for IL-17 TICI in the
corresponding recurrent carcinomas (p = 0.008).
FOXP3-positive immune cell infiltration in paired
primary and recurrent ovarian carcinoma
Six out of 13 (46.2 %) primary carcinomas of the chemore-
sistant and 9 out of 32 (28.1 %) of the chemosensitive subset
patients were positive for FOXP3 cell infiltration. The paired
recurrences showed 4 out of 13 (30.8 %) chemoresistant car-
cinomas and 10 out of 32 (31.2 %) chemosensitive carcinomas
to be positive for FOXP3. Seven patients that were negative in
their primary carcinomas turned to be positive for FOXP3 in
their recurrent tumors. Of these 7 patients, 2 were from the
chemoresistant subset. Another 7 patients were positive for
FOXP3 infiltration in the primary and recurrent carcinoma
samples (2 chemoresistant; 5 chemosensitive; Table 2).
Distribution of IL-17- and FOXP3-positive TICI
according to chemosensitivity
As shown in Fig. 2, IL-17-positive TICI frequency was
significantly higher in the chemosensitive group in all
Table 1 Patients’ characteristics according to dichotomized distribution of IL-17 and FOXP3 in the overall cohort
IL-17 high IL-17 low p value FOXP3 high FOXP3 low p value
N (%) N (%) N (%) N (%)
Age (median, range) 56 (34–73) 62 (39–77) 0.15 60 (34–73) 58 (39–77) 0.65
FIGO stagea
I 0 (0) 1 (3.8) 0.75 1 (6.7) 0 (0) 0.29
II 2 (10.5) 1 (3.8) 0 (0) 3 (10.0)
III 17 (89.5) 24 (92.4) 14 (93.3) 27 (90.0)
Resection statusa
0 6 (30.0) 10 (38.5) 0.84 4 (26.7) 11 (36.7) 0.79
1 10 (50.0) 7 (26.9) 6 (40.0) 11 (36.7)
2 4 (20.0) 9 (34.6) 5 (33.3) 8 (26.6)
Chemotherapya
\6 cycles 2 (8.7) 5 (21.7) 0.44 2 (13.3) 5 (16.7) 0.99
6 or more cycles 21 (91.3) 18 (78.3) 13 (86.7) 25 (83.3)
RFS (mean/SE)b 14.5 ± 2.3 6.4 ± 1.4 0.01 10.6 ± 2.4 9.9 ± 1.7 0.44
OS (mean/SE)b 55.7 ± 9.0 35.8 ± 4.3 0.05 44.6 ± 10.0 40.9 ± 4.2 0.59
Missing clinicopathological information was assumed to be missing at random
a Fisher’s exact test
b RFS recurrence-free survival, OS overall survival; p values were calculated according to the log rank test
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biopsies (n = 94, p = 0.001) as well as in biopsies of
primary (n = 47, p = 0.01) and matched recurrent
(n = 47, p = 0.04) carcinomas. For FOXP3-positive cell
infiltration, no association with sensitivity to platinum-
based chemotherapy could be determined in any of the
three groups (p = 0.53, p = 0.35 and p = 0.91, respec-
tively; Fig. 2).
Prognostic significance of IL-17- and FOXP3-positive
tumor immune cell infiltration
In the overall cohort of primary and matched recurrent
ovarian carcinomas, IL-17 (n = 47) had a positive prog-
nostic effect in univariate analysis (p = 0.045). However,
both markers were devoid of any prognostic effect in
multivariate analysis.
Correlation analysis of IL-17- and FOXP3-positive
tumor immune cell infiltration
To obtain more information about the relationship of the
two different subsets of immune cells, a correlation anal-
ysis of IL17- and FOXP3-positive cells was performed.
However, IL-17- and FOXP3-positive TICI did neither
correlate significantly in all biopsies (rs = 0.17; p = 0.1)
nor in biopsies of only primary (rs = 0.05; p = 0.73) or
recurrent carcinomas (rs = 0.29; p = 0.054).
Discussion
Adjuvant platinum-based chemotherapy after surgical
tumor debulking is a standard procedure. It would be
helpful to find markers that help predict response to che-
motherapy, in order to include extended chemotherapy
regimen and repetitive surgical procedures. Although our
previous studies identified potential therapeutical targets in
chemoresistant ovarian carcinomas, a reliable predictive
marker was not detected (Stadlmann et al. 2006, 2007a, b,
2008).
In this study, we found that IL-17-positive TICI was
significantly more frequent in the chemosensitive ovarian
carcinoma group. The presence of IL-17 positivity was
found to be very similar in primary and recurrent tissues.
IL-17-positive TICI was retained in 45 % (9/20) of recur-
rent carcinomas. Even though that in another 45 % (21/47),
the IL-17 status between primary and recurrent tumors
switched from positive to negative or vice versa IL-17-
positive biopsies were still increased in numbers in the
chemosensitive group. Therefore, IL-17 may keep its
indicative value for response to platinum-based chemo-
therapy in recurrent carcinomas. On the other hand, these
tumors might simply be less aggressive, either due to host
immune or other factors.
FOXP3 is a transcription factor that is mainly expressed
in so called regulatory cells with immunosuppressive
function (Zou 2006; Tang and Bluestone 2008). In ovarian
cancer, FOXP3 positive Treg cell infiltration has been
shown to be associated with significantly worse survival. In
this study, FOXP3-positive TICI had no predictive value
for response to chemotherapy.
Reviewing the literature, there is an ongoing search for
reliable prognostic and predictive markers in ovarian can-
cer. There is a trend toward individualized treatment based
on chemosensitivity assays or gene microarray analyses
(Kigawa et al. 2001; Sato et al. 1999). Tumor immune
response is known to play a major role in the control of
tumor progression in different types of cancer. Tumor
infiltration by CD8-positive T cells has been shown to
represent an important prognostic factor in melanoma
(Oble et al. 2009) and, more recently, in colorectal cancers
(Galon et al. 2006; Pages et al. 2005). Early studies have
also suggested a favorable prognostic effect of lymphocyte
infiltration in breast cancers (Menard et al. 1997). More
recently, tumor infiltration by CD3-positive T cells has
been proposed to predict responsiveness to neoadjuvant
treatment in breast cancer (Denkert et al. 2010). Further-
more, a predictive effect of breast cancer infiltration by
FOXP3-positive cells has also been reported (de Kruijf
et al. 2010). More aggressive tumors are growing faster and
therefore may produce stromal damage possibly related to
local hypoxia with necrotic areas (Minervini et al. 2008;
Table 2 Dichotomized distribution of IL-17 and FOXP3 according
to defined cutoff (1 cell/punch) in primary and matched recurrent
carcinomas
Chemoresistant
tumors
Chemosensitive
tumors
p value
n = 14 (100 %) n = 33 (100 %)
IL-17
Primary
Positive 2 (14.3) 18 (54.5) 0.02
Negative 12 (85.7) 15 (45.5)
Recurrent
Positive 2 (14.3) 17 (51.5) 0.02
Negative 12 (85.7) 16 (48.5)
n = 13 (100 %) n = 32 (100 %)
FOXP3
Primary
Positive 6 (46.2) 9 (28.1) 0.3
Negative 7 (53.8) 23 (71.9)
Recurrent
Positive 4 (30.8) 10 (31.2) 1.0
Negative 9 (69.2) 22 (68.8)
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Osinsky et al. 2009; De Schutter et al. 2005; Ben Shoshan
et al. 2008). Increased numbers of CD4- and FOXP3-
positive cells under hypoxic condition could be shown in
several studies (Ben Shoshan et al. 2008). Altogether the
pattern of immune cell infiltration in solid tumors most
likely reflects the state of tumor microenvironment and
consequently might predict response to chemotherapy in
ovarian cancer (Polcher et al. 2010).
Th17 cells, a subset of CD4? T cells characterized by
the secretion of high levels of IL-17A, IL-17F and IL-22,
play an important role in both the immune response to
invading pathogens and autoimmunity as well as transplant
rejection (Bettelli et al. 2008). The specific role of IL-17-
positive TICI in ovarian cancer is still debated. There is
increasing evidence that IL-17 can be produced by granu-
locytes (Li et al. 2010; Lin et al. 2011) and other immune
cells of the innate immune system (Cua and Tato 2010). In
ovarian cancer, it was shown that CD4-positive Treg cells
could be converted into proinflammatory interleukin
17-producing helper T cells (Leveque et al. 2009). Kryczek
et al. (2009) showed that a high density of IL-17-positive
TICI is associated with better survival. On the other hand,
steady production of TNF-alpha in the tumor microenvi-
ronment could increase myeloid cell recruitment in an IL-
17-dependent manner and contribute to tumor promotion
(Charles et al. 2009).
The main limitations of this study are a possible sampling
error, but pooling of primary and recurrent samples (n = 94
and n = 90, respectively) confirmed that IL-17, but not
FOXP3-positive TICI was significantly more frequent in
biopsies of chemosensitive than in biopsies of chemoresis-
tant tumors (Fig. 2). The potential problem of sufficient
sampling is negligible regarding the statistical significance
of our results since the low cut off level of one single positive
cell/core was applied to all cases and all cores.
In conclusion, IL-17-positive immune cell infiltration
could be a promising predictive marker in ovarian carci-
noma. It remains to be confirmed in larger series. Fur-
thermore, it would be interesting to investigate if IL-17
might also be of predictive value for second-line (platinum-
based) chemotherapy in ovarian carcinoma.
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